SARS-CoV-2 S1 ORF Mammalian 

To Order Contact us: stephen@expresspharmapulse.com

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag

E80020
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag

E80022
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag

E80025
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

Spike S1 RBD, His-tag (SARS-CoV-2)

100687-2 100 µg
EUR 520
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Spike S1 RBD, Fc fusion (SARS-CoV-2)

100699-2 100 µg
EUR 520
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)

100684-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)

100696-2 1 mg
EUR 3200
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike Trimer (S1+S2), His-tag (SARS-CoV-2)

100728-2 1 mg
EUR 2995
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)

100938-2 50 µg
EUR 555
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike Trimer (S1+S2), His-tag (SARS-CoV)

100789-2 500 µg_x000D_
EUR 1900
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag

E80024-2 1 ml
EUR 4995.1

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion

E80026-2 50 ul
EUR 823.9

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)

100698-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Avi-His-tag (SARS-CoV-2)

100730-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685 with a C-terminal Avi-His-tag, expressed in a HEK293 expression system, MW=78 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)

100769-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)

100846-2 1 mg
EUR 2600
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2)

100992-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. 

3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate

79952-2 10 mg
EUR 3460
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹.

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag

E80027
  • EUR 635.80
  • EUR 4087.60
  • 1 ml
  • 100 ul

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag

E80021-2 1 ml
EUR 4276.8

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag

E80023-2 1 ml
EUR 3934.7

Spike S1-Biotin (SARS-CoV-2): ACE2 TR-FRET Assay Kit

79949-2 384 rxns.
EUR 1265
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection._x000D_The SARS-CoV-2 Spike S1:ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 and human ACE2 in a homogeneous 96 or 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, dye-labeled acceptor and an inhibitor for one hour. Then the TR-FRET signal is measured using a fluorescence reader._x000D_ 

Spike S1 (13-665), Fc Fusion, Avi-tag (SARS-CoV-2)

100678-2 1 mg
EUR 3000
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag, Biotin-labeled (SARS-CoV-2)

100697-2 50 µg
EUR 480
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2)

100719-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, His-Avi-Tag, Biotin-Labeled (SARS-CoV-2)

100937-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This construct contains a C-terminal His-tag (6xHis) followed by an Avi-Tag. The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

Spike S1 (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)

101001-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.7 identified in the United Kingdom and contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6His). The recombinant protein is ≥90% pure following affinity purification.

Spike S1 (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)

101081-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein contains three mutations of interest K417T, E484K and N501Y, in addition to 682RRAR685>A. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified.

Spike S1 (B.1.617.2 Variant) Avi-His-Tag (SARS-CoV-2)

101151-2 1 mg
EUR 2995
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.617.2, also known as variant Delta originally discovered in India, and contains mutations T19R, G142D, R158G, L452R, T478K, D614G and P681R as well as deletion E156-F157. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. 

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial

E80028
  • EUR 388.30
  • EUR 860.20
  • 20 ul
  • 100 ul

Spike (SARS-CoV-2) Lentivirus

78010-2 500 µl x 2
EUR 2095
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

3CL Protease (SARS-CoV-2)

100823-2 500 µg_x000D_
EUR 3360
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa.

Anti-CoV-2 & SARS-CoV S1 Antibody (Clone# CR3022)

A2103-200 200 µg
EUR 576

Anti-SARS-CoV-2 Spike S1 Antibody

A3000-50 50 µg
EUR 502.8

Anti-Spike S1 Antibody (SARS-CoV-2)

100715-1 20 µg
EUR 300
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag

E80020-2 1 ml
EUR 4276.8

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag

E80022-2 1 ml
EUR 4276.8

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag

E80025-2 1 ml
EUR 3934.7

Spike Trimer (S1+S2) (B.1.351 Variant), His-Tag (SARS-CoV-2)

510333-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 South African Variant B.1.351 and contains mutations K417N, E484K and N501Y. It also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification._x000D_

Spike Trimer (S1+S2) (B.1.1.7 Variant), His-Tag (SARS-CoV-2)

510334-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 United Kingdom Variant B.1.1.7. It contains mutations N501Y, A570D, D614G, P681H, T716I, S982A, D1118; deletions: 21765:6 (69-70HV), 21991:3 (44Y).  This construct also contains a C-terminal His tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Spike S1 RBD, Fc-Fusion, Avi-Tag, Biotin-labeled (SARS-CoV-2)

100695-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90% MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

100731-2 50 µg
EUR 455
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™.

Spike Trimer (S1+S2) (K417T, E484K, N501Y), His- Tag (SARS-CoV-2)

100988-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein contains three mutations: K417T, E484K and N501Y that have been found in emerging SARS-CoV-2 Variants of Concern and may lead to higher transmissibility and infectivity. This mutant Spike Trimer will be useful for structure-function studies, testing of neutralizing antibodies, or antibody and drug screening.  _x000D_The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ?90% pure following affinity purification.

Spike Trimer (S1+S2) (P.1 Variant), His-Tag (SARS-CoV-2)

100989-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 Variant P.1 originally discovered in Brazil and contains 11 mutations in addition to 682RRAR685>A, K986P and V987P, as listed below. The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Spike S1 RBD (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)

100993-2 1 mg
EUR 2995
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to the RBD of SARS-CoV-2 Variant P.1, originally discovered in Brazil, and contains the three mutations  K417T, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following affinity purification.

Spike S1 RBD (B.1.617 Variant), Avi-His-Tag (SARS-CoV-2)

101156-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally identified in India, and contains mutations L452R and E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2)

100679-2 50 µg
EUR 450
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2)

100720-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation.

Spike S1 (P.1 Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

101080-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant P.1, also known as variant Gamma originally discovered in Brazil, and contains all ten P.1 mutations, as listed below. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike S1 (K417T, E484K, N501Y), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

101082-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein contains three mutations of interest K417T, E484K and N501Y (found in the RBD domain of some variants of concern). The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike S1 (B.1.617.1 Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

101125-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.1, also known as variant Kappa, originally identified in India. It contains mutations G142D, E154K, L452R, E484Q, D614G, and P681R. The construct also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike Trimer (S1+S2) (B.1.617.1, Kappa Variant), His-Tag (SARS-CoV-2)

101144-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.1 also known as variant Kappa originally identified in India, and contains mutations G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (XBB, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101660-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

PLPro, His-tag (SARS-CoV-2)

100735-2 1 mg
EUR 3000
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa.

NSP10/NSP16 Complex (SARS-CoV-2)

100747-2 1 mg
EUR 2500
Description: Complex of SARS-CoV-2 nonstructural protein 10 (NSP10), GenBank Accession No. YP_009725306.1, a.a. 1-139(full length), with N-terminal FLAG-tag, MW=16 kDa and SARS-CoV-2 nonstructural protein 16 (NSP16), Genbank Accession No. YP_009725311, a.a. 1-298(full length), with N-terminal His-tag, MW=34 kDa, co-expressed in a HEK293 cell expression system.

NSP7, His-tag (SARS-CoV-2)

100829-2 1 mg
EUR 2600
Description: SARS-CoV-2 nonstructural protein 7 (NSP7), Genbank Accession No.: YP_009742614, a.a. 1-84(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 10 kDa.

NSP8, His-tag (SARS-CoV-2)

100830-2 1 mg
EUR 2730
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa.

Anti-Nucleocapsid Antibody (SARS-CoV-2 )

100861-2 100 µg
EUR 420
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Nucleocapsid (N) protein.

ORF9b, GST-Tag (SARS-CoV-2)

100962-2 1 mg
EUR 2720
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification.

SARS-CoV-2 (COVID-19) Spike S1 Antibody

9083-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike S1 Antibody

9083-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

10-409 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

10-422 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

10-423 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2(COVID-19) S1 Recombinant Protein

10-424 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

10-428 0.1 mg
EUR 651.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

92-727 0.05 mg
EUR 468.6
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

92-731 0.05 mg
EUR 556.8
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

97-086 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

97-087 0.1 mg
EUR 752.1
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) S1 Recombinant Protein

97-092 0.1 mg
EUR 714.3
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Spike S1 RBD, His-tag (SARS-CoV-2)

100687-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Spike S1 RBD, Fc fusion (SARS-CoV-2)

100699-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag Biotin-labeled (SARS-CoV-2) HiP™

100770-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (B.1.617.2, Delta Variant) Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

101152-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike Trimer (S1+S2) (BA.2.3.20, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101654-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.3.20 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101655-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101656-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant+K444T), His-Tag (SARS-CoV-2)

101657-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 plus mutation K444T. Thus, it contains all the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BN.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101659-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BN.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (XBB.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101661-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.5, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101662-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.5 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.4.6, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101664-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.4.6 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BQ.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101665-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BQ.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BQ.1.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101666-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BQ.1.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (XBB.1.5, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant

101677-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB.1.5 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

3CL Protease (SARS-CoV-2) Assay Kit

79955-2 384 rxns.
EUR 1265
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. 3CL inhibitor GC376 is also included as an inhibitor control.

Spike S2, Fc-Tag (SARS-CoV-2)

100895-2 500 µg_x000D_
EUR 1815
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa.

Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag (SARS-CoV-2) HiP™

101153-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 (B.1.1.529 BA.1, Omicron Variant), Avi-His-Tag, (SARS-CoV-2) Recombinant

101333-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.529 BA.1, also known as variant Omicron BA.1 originally identified in South Africa, and contains genetic alterations indicated below. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant+V445P+F490S), His-Tag (SARS-CoV-2)

101658-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 plus mutations V445 and F490S. Thus, it contains all the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin)

9083-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin)

9083-biotin-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

21-805 50 ug
EUR 468.6
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

21-807 50 ug
EUR 437.1
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells.The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) is used as antigen in the Serological ELISA Kit to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma (see SARS-CoV-2 (Spike RBD) IgG Serological ELISA Kit; AG-45B-0020).

SARS-CoV-2 (COVID-19) S1 Recombinant Protein NTD

11-198 0.1 mg
EUR 714.3
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

10-107 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

10-109 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

10-111 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

10-118 0.1 mg
EUR 651.3
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

10-207 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

10-209 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

10-300 0.1 mg
EUR 632.4
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

SARS-CoV-2 (COVID-19) S1 (D614G) Recombinant Protein

92-746 0.05 mg
EUR 500.1
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant SARS-CoV-2 Spike Protein S1 (His-tag)

P1540-10 10 µg
EUR 211.2

Recombinant SARS-CoV-2 Spike Protein S1 (His-tag)

P1540-50 50 µg
EUR 818.4

Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag)

P1541-10 10 µg
EUR 211.2

Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag)

P1541-50 50 µg
EUR 818.4

SARS-CoV-2 (COVID-19) S1 RBD Detection Set

SD9400 1 Set
EUR 569.4
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)

100684-1 20 µg
EUR 295
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc fusion (SARS-CoV-2)

100688-1 20 µg
EUR 405
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)

100696-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike Trimer (S1+S2), His-tag (SARS-CoV-2)

100728-1 100 µg
EUR 350
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)

100938-1 20 µg
EUR 420
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)

100938-3 100 µg
EUR 740
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-2)

100792 100 µg
EUR 460
Description: Recombinant human monoclonal (clone 414-2) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S1 (B.1.1.529 BA.1, Omicron Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)

101334-2 100 µg
EUR 665
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.529 BA.1, also known as variant Omicron BA.1 originally identified in South Africa, and contains genetic alterations indicated below. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis).  The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag

E80027-2 100 ul
EUR 4087.6

3CL Protease, Untagged (SARS-CoV-2) Assay Kit

78042-2 384 rxns.
EUR 1210
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease sactivity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps.

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

79942-2 500 µl x 2
EUR 4405
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

79981-2 500 µl x 2
EUR 5245
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

3CL Protease (Mpro), MBP-tag (SARS-CoV-2)

100707-2 1 mg
EUR 2535
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), with an N-terminal MBP-tag, expressed in an E. coli expression system, MW=77.5 kDa.

Nucleocapsid Protein, Avi-His-tag (SARS-CoV-2)

100778-2 1 mg
EUR 2730
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

SARS-CoV-2 S1 ORF Mammalian